The Target Malaria research consortium, based at Imperial College London, is advancing field research on gene drive technology in Africa as a potential tool to reduce populations of malaria-transmitting mosquitoes. The non-profit initiative is currently conducting studies in Burkina Faso, Ghana, Mali, and Uganda, focusing on the Anopheles gambiae mosquito species, a primary vector of the disease.
Gene drive is a genetic engineering technique designed to spread a specific trait, such as infertility or female sterility, through a wild population much faster than normal inheritance. The goal is to suppress mosquito populations, thereby reducing malaria transmission. Target Malaria emphasizes that its work is at the research and development stage, with extensive regulatory review and community engagement being integral parts of the process.
Malaria remains a major public health challenge in Africa, with the World Health Organization reporting an estimated 608,000 deaths globally in 2022, the vast majority in the African region. While current interventions like insecticide-treated nets and antimalarial drugs have saved lives, insecticide resistance and other challenges necessitate the exploration of complementary tools.
The development of gene drive mosquitoes involves complex ethical, regulatory, and environmental safety considerations. Target Malaria states it is committed to a stepwise testing approach, with current releases involving genetically modified non-gene drive male mosquitoes that are sterile. Further releases of gene drive organisms would require additional national and local approvals.
